A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer.

ABSTRACT:

Background

To investigate the efficacy of palbociclib plus endocrine therapy (ET) as the initial treatment compared with post-chemotherapy maintenance therapy in the first-line treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer (MBC).

Methods

A total of 110 patients with HR-positive HER2-negative MBC were enrolled in this study between 2018 and 2023. Progression-free-survivals (PFS) and Overall Survival (OS) of palbociclib plus ET as the initial treatment (group A, n:78) or as post-chemotherapy maintenance therapy (group B, n:32) were calculated. We used the multivariable Cox model to investigate the relationship between each factor and prognosis and performed subgroup analysis.

SUBMITTER: Li X 

PROVIDER: S-EPMC12283718 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature